St.Vincents ASCENSION	Attendance F	Roster	Instructor: OUTSIDE
<ul> <li>▶ HEALTH SYSTEM   Z</li> <li>▶ Date: April 17, 2018</li> <li>▶ Inter-professional □ Single Discipline</li> </ul>	"Changing Lands Interstitial Lung	-	Dr. David Lederer, MS Credits: 1.00 Direct Sponsored Jointly Sponsored
Please Check One:       St. Vincent's Birm         St. Vincent's East       St. Vincent's St.		t's Blount 🗌 One Nineteen 🛛	St. Vincent's Chilton
Name <mark>(Please Print)</mark>	Hospital/Ministry/ Business	(Pharmacy) DOB & NAB	
			MD DO PA RN Pharmacist RPh Pharmacy Tech OT PT Social Worker Student Other
			MD DO NP PA RN Pharmacist RPh Pharmacy Tech OT PT Social Worker Student Other
			MD DO NP PA RN Pharmacist RPh Pharmacy Tech OT PT Social Worker Student Other
			MD DO NP PA RN Pharmacist RPh Pharmacy Tech OT PT Social Worker Student Other
			MD DO NP PA RN Pharmacist RPh Pharmacy Tech OT PT Social Worker Student Other
			MD DO NP PA RN Pharmacist RPh Pharmacy Tech OT PT Social Worker Student Other
			MD       DO       NP       PA         RN       Pharmacist       RPh         Pharmacy Tech       OT       PT         Social Worker       Student       Other
			MD DO PA RN Pharmacist RPh Pharmacy Tech OT PT Social Worker Student Other
<b>Physicians:</b> St. Vincent's Health System is accred for physicians. Designation Statement: The St. Vince			

1.00 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurse:** Ascension Health is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Provider Number: P0340. This activity is approved for 1.0 Contact Hours continuing education.

**Pharmacists:** The St. Vincent's Health System is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Completion of this knowledge-based activity provides for 1.0 contact hour (0.1 CEU) of continuing pharmacy education credit.

**Faculty/Course Director/Planners:** STVHS has selected all faculty participating in this activity. It is the policy of STVHS that all CME/CE planning committees, faculty, authors, editors, and staff disclose relationships with commercial interests upon nomination or invitation of participation. Disclosure documents are reviewed for potential conflicts of interest and if relevant, they are resolved prior to confirmation of participation. Only those participants who have no conflict of interest or who agreed to an identified resolution process prior to their participation were involved in this activity.

Please scan back for credit to: <a href="mailto:lisa.davis2@ascension.org">lisa.davis2@ascension.org</a> (Info must be completely filled out for credit)

### PENN STATE COLLEGE OF MEDICINE EVALUATION

### The Changing Landscape of Interstitial Lung Disease

DATE: 4/17/18 PLACE: ST VINCENT HEALTH, BIRMINGHAM, AL COURSE # G6189M-18-Z Penn State College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. To receive a CME certificate, complete the form below, return it to the registration table, or mail to:

Penn State Continuing Education, MC G220 PO Box 851 Hershey, PA 17033-0851

For questions about your CME credit, contact Penn State Continuing Education at 717-531-6483 or via email at ContinuingEd@hmc.psu.edu.

Name (please print)	-					Degree	
Address	•						
City				State		Zip Code	
Email (CME certificate	will b	e sent to this email)				plane in energy	
Phone (to contact you	if we	have questions about yo	our C	ME certificate)	algester (*)		
I verify that I have com	pleted	this CME activity (sign	ature	)			
Actual time spent on th	e acti	vity (up to 1.0 hour)					
Please fill in the circles Select one:	com	uture course developme pletely using a dark pen	or pe	encil.			
O Physician	0	Resident Physician	0	Physician Assistant	C	Nurse Practitioner	

0 Registered Nurse O Student

Resident Physician O Physician Student O Other \_\_\_\_

### **OVERALL EVALUATION**

Please rate your level of agreement with each of the following statements:

		Strongly disagree 1	Disagree 2	Neutral 3	Agree 4	Strongly agree 5
1.	The content and format were effective in meeting the educational objectives.	0	0	0	0	0
2.	The content promotes improvements or quality in health care.	0	0	0	0	0
3.	The material presented was organized and easy to follow.	0	0	0	0	0
4.	The content was useful and relevant to my practice.	0	0	0	0	0
5.	The content was scientifically balanced and based on best available evidence and best practices in medicine.	0	0	0	0	0
6.	The content was presented objectively and without commercial bias.	0	0	0	0	0

If you perceived commercial bias, what factors do you believe contributed to the bias?

**Objectives** 

Ba	sed on this program, I am now better able to:	Strongly disagree 1	Disagree 2	Neutral 3	Agree 4	Strongly agree 5
1.	Review the diagnosis and classification of ILD disorders.	0	0	0	0	0
2.	Discuss advances in ILD diagnosis and assessment.	0	0	0	0	0
3.	Outline treatment strategies for ILD.	0	0	0	0	0
4.	Recognize the importance of treating comorbidities.	0	0	0	0	0

### **Impact on Practice**

1. Choose the statement(s) that apply:

- O I gained new strategies/skills/information that I can apply in my practice
- O I plan to implement new strategies/skills/information into my practice
- O I plan to make changes in my practice, which will likely improve the health of my patients
- O This activity will not change my practice, because my current practice is consistent with what was taught
- O This activity will not change my practice, because I do not agree with the information presented
- O Not applicable/I don't provide clinical services

2. What types of changes do you anticipate making? (choose all that apply)

- O Modify treatment plans
- O Change screening/prevention practices
- O Incorporate different diagnostic strategies
- O Change the way I communicate with patients, families, and the health care team
- O I do not expect to change my practice
- O Not applicable/I don't provide clinical services
- O Other

Please list specific strategies you plan to implement into your practice.

### **Barriers to Change/Factors that Impact Patient Outcomes**

(Choose all that apply. If you do not provide clinical services, leave this section blank.)

- O No barriers
- O More information is needed
- O Cost to patient
- O Lack of resources
- O Lack of consensus or professional guidelines
- O Other \_\_\_\_\_

- O Organizational or institutional barriers
- O Inadequate time to assess or counsel patients
- O Reimbursement or insurance issues
- O Patient compliance or adherence issues
- O Staff/coworker resistance

# COMMENTS

. . .

Your comments are very helpful in planning future activities. Feel free to use the space below for written comments.

Comments related to program content:

Please describe any problems you have encountered in your practice that you would like to see addressed in a future CME activity:

## The Changing Landscape of Interstitial Lung Disease PRE-PROGRAM SURVEY PLEASE COMPLETE THIS SIDE BEFORE THE PROGRAM

Please help us assess the quality and effectiveness of this program by completing this brief survey. Please give your completed surveys and evaluation to your site coordinator, or mail them to MCM Education, 17 Blacksmith Rd., Suite 100, Newtown, PA 18940. NOTE: THIS IS NOT THE EVALUATION.

- 1. I am a:
  - o Physician
  - o Resident physician
  - o Physician assistant
  - o Nurse practitioner
  - o Registered nurse
  - o Student
  - Other (please specify): \_\_\_\_\_
- 2. My specialty is:
  - o Pulmonology
  - o Primary care/internal medicine
  - o Radiology
  - Other (please specify): \_\_\_\_\_
- 3. Which **one** of the following clinical features is **most characteristic** of early ILD? (Select only one response.)
  - o Stridor
  - Fine end-inspiratory crackles
  - o Expiratory wheeze
  - o Systemic/extrapulmonary symptoms
- You have a patient you suspect may have ILD. Which of the following tests would you order to obtain the most compelling evidence of ILD? (Select only one response.)

- o Pulmonary function testing
- o Chest X-ray
- o Echocardiogram
- o High resolution CT scan
- 5. Compared with placebo, which of the following has been shown to slow progression of disease (as defined by the rate of reduction in FVC) in patients with mild to moderate IPF?
  - o Pirfenidone
  - o Nintedanib
  - o Neither
  - o Both
- 6. Appropriate management of comorbidities can help to reduce ILD morbidity and mortality.
  - o True
  - o False
- The ATS/ERS/JRS/ALAT clinical practice guideline conditionally recommends the use of which of the following in patients with IPF? (Select only one response.)
  - Antacid therapy (proton pump inhibitors or histamine-2-receptor antagonists)
  - o Anticoagulation (warfarin)
  - Combination prednisone + azathioprine + N-acetylcysteine
  - o Phosphodiesterase-5 inhibitor

rease rate your current level of confidence to do each of the following (1=not at an confident; 5=very confident;						
	1	2	3	4	5	
Recognize the signs and symptoms that suggest ILD						
Evaluate a patient for ILD						
Develop timely, appropriate therapeutic interventions for patients with ILD						
Monitor patients with ILD for progressive disease						
Know when to refer patients to an ILD center or a pulmonologist specializing in ILD						

8. Please rate your current level of confidence to do each of the following (1=not at all confident; 5=very confident):

Thank you. Please do not complete the second side until after the program.

# The Changing Landscape of Interstitial Lung Disease POST-PROGRAM SURVEY

### PLEASE COMPLETE THIS SIDE AFTER THE PROGRAM

- 1. Approximately how many patients with *symptoms that could be suggestive* of ILD do you encounter in a month?
  - a. I do not encounter patients with symptoms that could be suggestive of ILD
  - b. <10
  - c. 10-25
  - d. 26-50
  - e. >50
- 2. Approximately how many patients *with* ILD do you encounter/treat in a month?
  - a. I do not encounter/treat patients with ILD
  - b. <10
  - c. 10-25
  - d. 26-50
  - e. >50
- 3. How many years have you been in practice?
  - o <5
  - o 5-10
  - o 11-15
  - o **16-20**
  - o **21-25**
  - o >25
- 4. Which **one** of the following clinical features is **most characteristic** of early ILD? (Select only one response.)
  - o Stridor
  - o Fine end-inspiratory crackles
  - o Expiratory wheeze
  - Systemic/extrapulmonary symptoms

- You have a patient you suspect may have ILD. Which of the following tests would you order to obtain the most compelling evidence of ILD? (Select only one response.)
  - o Pulmonary function testing
  - o Chest X-ray
  - o Echocardiogram
  - o High resolution CT scan
- 6. Compared with placebo, which of the following has been shown to slow progression of disease (as defined by the rate of reduction in FVC) in patients with mild to moderate IPF?
  - o Pirfenidone
  - o Nintedanib
  - o Neither
  - o Both
- 7. Appropriate management of comorbidities can help to reduce ILD morbidity and mortality.
  - o True
  - o False
- The ATS/ERS/JRS/ALAT clinical practice guideline conditionally recommends the use of which of the following in patients with IPF? (Select only one response.)
  - Antacid therapy (proton pump inhibitors or histamine-2-receptor antagonists)
  - Anticoagulation (warfarin)
  - Combination prednisone + azathioprine + N-acetylcysteine
  - o Phosphodiesterase-5 inhibitor

	1	2	3	4	5
Recognize the signs and symptoms that suggest ILD					
Evaluate a patient for ILD					
Develop timely, appropriate therapeutic interventions for patients with ILD					
Monitor patients with ILD for progressive disease					
Know when to refer patients to an ILD center or a pulmonologist specializing in ILD					

### 9. Please rate your current level of confidence to do each of the following (1=not at all confident; 5=very confident):

### Thank You for Your Participation.

Please leave your completed survey on the table or give it to the site coordinator. Please provide your email address if you will permit us to send you a follow-up survey to further assess our activities: \_\_\_\_\_\_